Evidence map›Paper›PMID 32757150›Full record

ArticleEJNMMI research2020

A new

Rosalba Mansi, Karim Abid, Guillaume P Nicolas, Luigi Del Pozzo, Eric Grouzmann, Melpomeni Fani

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Evaluation of a NewMolecules (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Rosalba MansiDivision of Radiopharmaceutical Chemistry, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
Karim AbidCatecholamine and Peptides Laboratory, Department of Laboratories, University Hospital of Lausanne, Lausanne, Switzerland.
Guillaume P NicolasDivision of Nuclear Medicine, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
Luigi Del PozzoDivision of Radiopharmaceutical Chemistry, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
Eric GrouzmannCatecholamine and Peptides Laboratory, Department of Laboratories, University Hospital of Lausanne, Lausanne, Switzerland.
Melpomeni FaniDivision of Radiopharmaceutical Chemistry, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland. melpomeni.fani@usb.ch.ORCID http://orcid.org/0000-0002-9309-1604
University Hospital of Basel · CHUniversity Hospital of Lausanne · CH

Funding

Kommission für Technologie und Innovation 16403.2 PFLS-LSKommission für Technologie und Innovation 18282.2 PFLS-LS
6 · The paper itself

Abstract

backgroundSomatostatin receptor (SST) targeting, specifically of the subtype 2 (SST2), with radiolabeled somatostatin analogs, is established for imaging and treatment of neuroendocrine tumors. Owing to the concomitant and heterogeneous expression of several subtypes on the same tumor, analogs targeting more subtypes than SST2 potentially target a broader spectrum of tumors and/or increase the uptake of a given tumor. The analog ST8950 ((4-amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH

resultsCompared with

conclusions[

Indexed as

68GaIodo-amino acidsNeuroendocrine tumorsPETSomatostatin agonistsSomatostatin receptor subtypesSST2SST5

Identifiers

PMID32757150
PMCPMC7406630
OpenAlexW3047379553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.